MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	~~10/664,421~~ 10/789,818
Filing Date	09/16/2003
First Named Inventor	Ryan Bremer
Group Art Unit	1656
Examiner Name	Nashed
Attorney Docket Number	039363-0703

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
NN	A1	20010008765		Shinoki et al.	07/19/2001	
	A2	20010012537		Anderson et al.	08/09/2001	
	A3	20010014448		Chappa et al.	08/16/2001	
	A4	20010014449		Nerenberg et al.	08/16/2001	
	A5	20010016322		Caren et al.	08/23/2001	
	A6	20010018642		Balaban et al.	08/30/2001	
	A7	20010019827		Dawson et al.	09/06/2001	
	A8	6100254		Budde et al.	08/08/2000	
NN	A9	6197495		Qui et al.	03/06/2001	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Application Document Serial Number	U.S. Patent Application Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
NN	A10	WO	99/26966		The Regents of the University of California	06-03-1999		
NN	A11	WO	01/58951		Stichting Voor de Technische Wetenschappen	08-16-2001		
NN	A12	WO	02/24722		Prochon Biotech Ltd.	03-28-2002		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]

Examiner Signature	/Nashaat Nashed/ (01/30/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	~~10/664,421~~ 10/789,818 Non
Filing Date	09/16/2003
First Named Inventor	Ryan Bremer
Group Art Unit	1656
Examiner Name	Nashed
Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
NN	A13	BOEHM, *et al.*, "Novel Inhibitors of DNA Gyrase: 3D Structure Based Biased Needle Screening, Hit Validation by Biophysical Methods, and 3D Guided Optimization. A Promising Alternative to Random Screening," *J. Med. Chem.* 43:2664-2674 (2000)	
	A14	BOHACEK, *et al.*, "Multiple Highly Diverse Structures Complementary to Enzyme Binding Sites: Results of Extensive Application of a *de Novo* Design Method Incorporating Combinatorial Growth," *J. Am. Chem. Soc.* 116:5560-5571 (1994)	
	A15	CHONG, *et al.*, "Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7," *PNAS* 96:14330-14335 (1999)	
	A16	CORNELL, *et al.*, "A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules," *J. Am. Chem. Soc.* 117:5179-5197 (1995)	
	A17	DONINI and KOLLMAN, "Calculation and Prediction of Binding Free Energies for the Matrix Metalloproteinases," *J. Med. Chem.* 43:4180-4188 (2000)	
	A18	DOWNS and WILLETT, "Similarity Searching and Clustering of Chemical-Structure Databases Using Molecular Property Data," *J. Chem. Inf. Comput. Sci.* 34:1094-1102 (1994)	
	A19	ELCOCK, Realistic modeling of the denatured states of proteins allows accurate calculations of the pH dependence of protein stability. J. Mol. Biol., 294:1051-1062, (1999).	
	A20	FELDER, "The Challenge of Preparing and Testing Combinatorial Compound Libraries in the Fast Lane, at the Front End of Drug Development," *Chimia* 48:531-541 (1994)	
	A21	GILLILAND and LADNER, Crystallization of biological macromolecules for X-ray diffraction studies. Current Opinion in Structural Biology, 6:595-603, 1996.	
	A22	JARVIS and PATRICK, "Clustering Using a Similarity Measure Based on Shared Near Neighbors," *IEEE Transactions on Computers* 11:1025-1034 (1973)	
	A23	KE and DOUDNA, Crystallization of RNA and RNA-protein complexes. Methods, 34:408-414, (2004).	
NN	A24	MASSOVA and KOLLMAN, "Computational Alanine Scanning to Probe Protein – Protein Interactions: A Novel Approach to Evaluate Binding Free Energies," *Journ. of Amer. Chem. Soc.* 121(36):8133-8143 (1999)	

Examiner Signature	/Nashaat Nashed/ (01/30/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	~~10/664,421~~ 10/789,818 AFE
Filing Date	09/16/2003
First Named Inventor	Ryan Bremer
Group Art Unit	1656
Examiner Name	Nashed
Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
NN	A25	MCGOVERN, *et al.*, "A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening," *J. Med. Chem.* 45:1712-1722 (2002)	
	~~A26~~	~~OBRECHT, *et al.*, "Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound Libraries," *Linker Mol. & Oligav. Strat.* P. 85.~~ Incomplete citation.	
NN	A27	OWEN, *et al.*, "Two Structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product," *Curr. Biol. Ltd.* 3:467-482 (1995)	
NN	A28	PEARLMAN and CHARIFSON, "Are Free Energy Calculations Useful in Practice? A Comparison with Rapid Scoring Functions for the p38 MAP Kinase Protein System," *J. Med. Chem.* 44:3417-3423 (2001)	
NN	A29	RIPKA, *et al.*, "Aspartic Protease Inhibitors Designed from Computer-Generated Templates Bind as Predicted," *Org. Lett.* 15:2309-2312 (2001)	
NN	A30	WIENCEK , New strategies for protein crystallization growth. Ann.Rev.Biomed.Eng., 1:505-534, (1999).	
NN	A31	WILLETT, "Chemical Similarity Searching," *J. Chem. Inf. Comput. Sci.* 38:983-996 (1998)	

Examiner Signature	/Nashaat Nashed/ (01/30/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	~~10/664,421~~ 10/789,818
				Filing Date	09/16/2003
				First Named Inventor	Ryan Bremer
				Group Art Unit	1656
(use as many sheets as necessary)				Examiner Name	Nashed
Sheet	4	of	4	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
NN	A32	YANG et al., Peptide analogs from E-cadherin with different calcium-binding affinities. J. Peptide Research, 55:203-215, 2000.	

Examiner Signature	/Nashaat Nashed/ (01/30/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/789,818
Filing Date	02/27/2004
First Named Inventor	Prabha Ibrahim
Art Unit	1656
Examiner Name	Nashed, Nashaat T.
Attorney Docket Number	039363-1202

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
~~NN~~	~~A1~~	~~US-5837524~~	~~11.17.1998~~	~~Schlessinger et al~~	
NN	A2	US-5942428	08.24.1999	Mohammadi et al.	
~~NN~~	~~A3~~	~~US-6100254~~	~~08.08.2000~~	~~Budde et al.~~	
~~NN~~	~~A4~~	~~US-6197493~~	~~03.06.2001~~	~~Qiu et al.~~	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Application Document Serial Number-Kind Code[2] (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
NN	A5	Cohen et al., Molecular modeling software and methods for medicinal chemistry. Journal of Medicinal Chemistry, 33(3): 883-894, 1990.	
	A6	Gilliland and Ladner, Crystallization of biological macromolecules for X-ray diffraction studies. Current Opinion in Structural Biology, 6:595-603, 1996.	
	A7	Ke and Doudna, Crystallization of RNA and RNA-protein complexes. Methods, 34:408-414, 2004.	
	A8	Wiencek et al, New strategies for protein crystal growth. Annual Review of Biomedical Engineering, 01:505-534, 1999.	

Examiner Signature	/Nashaat Nashed/ (01/30/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/789,818
				Filing Date	02/27/2004
				First Named Inventor	Prabha Ibrahim
				Art Unit	1656
(use as many sheets as necessary)				Examiner Name	Nashed, Nashaat T.
Sheet	2	of	2	Attorney Docket Number	039363-1202

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
NN	A9	International Search Report for PCT Application PCT/US2004/005904	

Crossed over references are duplicates of other IDS's.

Examiner Signature	/Nashaat Nashed/ (01/30/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 6

Complete If Known	
Application Number	10/789,818
Filing Date	02/27/2004
First Named Inventor	Prabha Ibrahim
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	039363-1202

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
NN	A1	5698401		Fesik et al.	12-16-1997	
NN	A2	5804390		Fesik et al.	09-08-1998	
	~~A3~~	~~6197495~~		~~Qui et al.~~	~~03-06-2001~~	
	A4	6297021		Nienaber et al.	10-02-2001	
NN	A5	6465484		Bilodeau et al.	10-15-2002	
	A6	20020048782		Lev et al.	04-25-2002	
	~~A7~~	~~20010008765~~		Shinoki, Hiroshi et al.	07/19/2001	
	A8	20010012597		Anderson, Norman G. et al.	08/09/2001	
	A9	20010014448		Chappa, Ralph A. et al.	08/16/2001	
	A10	20010014449		Nerenberg, Michael et al.	08/16/2001	
	A11	20010016322		Caren, Michael P. et al.	08/23/2001	
	A12	20010018642		Balaban, David et al.	08/30/2001	
	~~A13~~	20010019827		Dawson, Elliott P. et al.	09/06/2001	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Application Document Serial Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
NN	A14	EP	0,154,734		Immunex Corporation	08-29-1990		
NN	A15	WO	96/18738		Sugen, Inc.	06-20-1996		
NN	A16	WO	97/46313		Array Technologies	12-11-1997		
NN	A17	WO	98/35056		Merck & Co., Inc.	08-13-1998		
NN	A18	WO	99/63931		The Salk Institute for Biological Studies	12-16-1999		
NN	A19	WO	99/09217		Hyseq, Inc.	02-25-1999		

Crossed over refrences are duplicate, See other IDS's

Examiner Signature	/Nashaat Nashed/ (01/30/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/789,818
				Filing Date	02/27/2004
				First Named Inventor	Prabha Ibrahim
				Group Art Unit	1646
(use as many sheets as necessary)				Examiner Name	
Sheet	2	of	6	Attorney Docket Number	039363-1202

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	~~A20~~	~~WO~~	~~99/20960~~		~~The Regents of the University of California~~	~~06-03-1999~~		
NN	A21	WO	99/51773		Phylos, Inc.	10-14-1999		
NN	A22	WO	01/58951		Stichting Voor de Technische Wetenschappen	08-16-2001		
	~~A23~~	~~WO~~	~~02/24722~~		~~Prochon Biotech Ltd.~~	~~03-28-2002~~		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
NN	A24	Ashani and Wilson, A covalent affinity column for the purification of acetylcholinesterase. Biochem. Biophys. Acta, 276:317-322, 1972.	
	~~A25~~	~~BOEHM, *et al.*, "Novel Inhibitors of DNA Gyrase: 3D Structure Based Biased Needle Screening, Hit Validation by Biophysical Methods, and 3D Guided Optimization. A Promising Alternative to Random Screening," *J. Med. Chem.* 43:2664-2674 (2000)~~	
	A26	BOHACEK, *et al.*, "Multiple Highly Diverse Structures Complementary to Enzyme Binding Sites: Results of Extensive Application of a *de Novo* Design Method Incorporating Combinatorial Growth," *J. Am. Chem. Soc.* 116:5560-5571 (1994)	
	A27	CHONG, *et al.*, "Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7," *PNAS* 96:14330-14335 (1999)	
NN	A28	COE and STORER, "Solution-phase combinatorial chemistry." Molecular Diversity, 4:1-38, 1999.	
	~~A29~~	~~CORNELL, *et al.*, "A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules," *J. Am. Chem. Soc.* 117:5179-5197 (1995)~~	
	A30	DONINI and KOLLMAN, "Calculation and Prediction of Binding Free Energies for the Matrix Metalloproteinases," *J. Med. Chem.* 43:4180-4188 (2000)	

Examiner Signature	/Nashaat Nashed/ (01/30/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/789,818
				Filing Date	02/27/2004
				First Named Inventor	Prabha Ibrahim
				Group Art Unit	1646
(use as many sheets as necessary)				Examiner Name	
Sheet	3	of	6	Attorney Docket Number	039363-1202

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	~~A31~~	~~DOWNS and WILLETT, "Similarity Searching and Clustering of Chemical-Structure Databases Using Molecular Property Data," *J. Chem. Inf. Comput. Sci.* 34:1094-1102 (1994)~~	
	A32	ELCOCK, Realistic modeling of the denatured states of proteins allows accurate calculations of the pH dependence of protein stability. Journal of Molecular Biology, 294:1051-1062, 1999.	
	A33	FEINBERG et al., Zinc-directed inhibitors for zinc proteinases. Acta Cryst., D51: 428-449, 1995.	
	A34	FELDER, E.R., "The Challenge of Preparing and Testing Combinatorial Compound Libraries in the Fast Lane, at the Front End of Drug Development," *Chimia* 48:531-541 (1994)	
NN	A35	FITZGERALD et al., Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. The Journal of Biological Chemistry, 265 (24): 14209-14219, 1990.	
NN	A36	GELLER et al., HIV-1 protease and its inhibitors in Theoretical and Computational Mthods in Genome Research. Edited by Sahai. New York: Plenum Press, 1997, p. 237-254.	
NN	A37	HENDRICKSON and OGATA, "Phase Determination from Multiwavelength Anomalous Diffraction Measurements," *Methods of Enzymology* 276:494-523 (1997)	
NN	A38	HENDRICKSON *et al.*, "Selenomethionyl Proteins Produced for Analysis by Multiwavelength Anomalouse Diffraction (MAD): a Vehicle for Direct Determination of Three-Dimensional Structure," *The EMBO Journal* 9(5):1665-1672 (1990)	
	~~A39~~	~~JARVIS and PATRICK, "Clustering Using a Similarity Measure Based on Shared Near Neighbors," *IEEE Transactions on Computers* 11:1025-1034 (1973)~~	
NN	A40	KLEINBERG and WANKE, New approaches and technologies in drug design and discovery. Am. J. Health-Syst Pharm., 52: 1323-1336, 1995.	
NN	A41	LEBL *et al.*, "One-Bead-One-Structure," *Biopolymers (Peptide Science)* 37:177-198 (1995)	
	~~A42~~	~~MASSOVA and KOLLMAN, "Computational Alanine Scanning to Probe Protein – Protein Interactions: A Novel Approach to Evaluate Binding Free Energies," *Journ. of Amer. Chem. Soc.* 121(36):8133-8143 (1999)~~	

Examiner Signature	/Nashaat Nashed/ (01/30/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

Complete If Known	
Application Number	10/789,818
Filing Date	02/27/2004
First Named Inventor	Prabha Ibrahim
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	039363-1202

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	~~A43~~	~~MCGOVERN, *et al.*, "A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High Throughput Screening," *J. Med. Chem.* 45:1712-1722 (2002)~~	
NN	A44	MCPHERSON et al., The Role of X-ray crystallography in structure-based rational drug designs. Chapter 6 in Chemical Structures Approaches Ration. Drug Design. Edited by D.V. Weiner et al. Boca Raton: CRC Press, 1995, p. 161-179.	
NN	A45	NAGAR *et al.*, "Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecular Inhibitors PD173955 and Imatinib (STI-571)," *Cancer Research* 62:4236-4243 (2002)	
	A46	OBRECHT, *et al.*, "Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound Libraries," *Linker Mol. & Cleav. Strat.* P. 85.	
	A47	OWEN, *et al.*, "Two Structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product," *Curr. Biol. Ltd.* 3:467-482 (1995)	
	A48	PEARLMAN and CHARIFSON, "Are Free Energy Calculations Useful in Practice? A Comparison with Rapid Scoring Functions for the p38 MAP Kinase Protein System," *J. Med. Chem.* 44:3417-3423 (2001)	
	A49	RIPKA, *et al.*, "Aspartic Protease Inhibitors Designed from Computer-Generated Templates Bind as Predicted," *Org. Lett.* 15:2309-2312 (2001)	

Examiner Signature	/Nashaat Nashed/ (01/30/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/789,818
				Filing Date	02/27/2004
				First Named Inventor	Prabha Ibrahim
				Group Art Unit	1646
(use as many sheets as necessary)				Examiner Name	
Sheet	5	of	6	Attorney Docket Number	039363-1202

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
NN	A50	ROSENBERRY et al., Purification of acetylcholinesterase by affinity chromatography and determination of active site stoichiometry. The Journal of Biological Chemistry, 247 (5): 1555-15565, 1972.	
NN	A51	SICA et al., Affinity chromatography and the purification of estrogen receptors. The Journal of Biological Chemistry, 248 (18): 6543-6558, 1973.	
	~~A52~~	~~WILLETT, P., "Chemical Similarity Searching," J. Chem. Inf. Comput. Sci. 38:983-996 (1998)~~	
NN	A53	WUTHRICH, NMR-This other method for protein and nucleic acid structure determination. Acta Cryst., D51: 249-270, 1995.	
	~~A54~~	~~YANG ET AL., Peptide analogs from E-cadherin with different calcium binding affinities. Journal of Peptide Research, 55:205-215, 2000.~~	
NN	A55	KEISS et al., Beta-Galactosidase decreases the binding affinity of the insulin-like-growth-factor-ii/mannose-6-phosphate receptor for the insulin-like-growth-factor II. European Journal of Biochemistry, 190:71-77, 1990	
NN	A56	BOS et al., The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology, 9:165-169, 2000.	

Examiner Signature	/Nashaat Nashed/ (01/30/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/789,818
				Filing Date	02/27/2004
				First Named Inventor	Prabha Ibrahim
				Group Art Unit	1646
(use as many sheets as necessary)				Examiner Name	
Sheet	6	of	6	Attorney Docket Number	039363-1202

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
NN	A57	BOGER et al., Synthesis of a functionalized rigid bicycle[2,2,1]heptane: a useful hapten for eliciting catalytic antibodies. Journal of Organic Chemistry, 59:5078-5079, 1994.	
NN	A58	PHAN et al., Extensively methylated myosin subfragment-1; Examination of local structure, interactions with nucleotides and actin, and ligand-induced conformational changes. Biochemistry, 33:11286-11295, 1994.	
NN	A59	MARYANOFF et al., Structure activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. Journal of Medicinal Chemistry, 41:1315-1343, 1998.	
NN	A60	MOCHIZUKI *et al.*, "Physical and Functional Interactions Between Pim-1 Kinase and Cdc25A Phosphatase," *The Journal of Biological Chemistry* 274:8659-18666, 1999	

Examiner Signature	/Nashaat Nashed/ (01/30/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.